Biocurate partnership: Triple Negative Breast Cancer Treatment

Monash University has received a grant from BioCurate’s ‘Proof of Concept Fund’ to undertake research to explore new treatment options for patients diagnosed with TNBC and other poor prognosis cancers. The research is being led by Professor Roger Daly, who heads Monash Biomedicine Discovery Institute’s (BDI) cancer program.

TNBC represents around 15 per cent of breast cancers, is aggressive and has limited treatment options. Chemotherapy is the most common treatment but has detrimental side effects that negatively affect quality of life. The award allocated via the BioCurate partnership will support key research needed to determine the effectiveness of targeting two proteins that promote the growth of TNBC. If successful, this could lead to a drug development program and ultimately novel, targeted treatments for TNBC and other poor prognosis cancers. To date key outcomes of the research, include:

  • Identifying two proteins required by TNBC cells to grow. These proteins represent potential targets for small molecule drugs that could be used to treat this type of cancer.
  • Progress towards the diversification of treatment options for patients with aggressive cancer, such as TNBC.
  • Further promotion of Monash University’s strong links with industry.
  • Positioning Monash University as a leader in biomedical research.

BioCurate is part of the Monash Technology Precinct, Victoria’s second largest employment precinct outside the CBD, and one of Australia’s most diverse ecosystems of globally-connected innovators and enterprise across future technologies, advanced manufacturing, health, sustainable development and education.



Find out more about Biocurate.

Explore Monash Biomedicine Discovery Institute.